Results 121 to 130 of about 88,182,083 (298)
Short‐term codeine administration (1–3 days) caused individual alterations in Athlete Biological Passport steroid markers, including elevated urinary T/E ratios and decreased serum testosterone concentrations below individual thresholds, despite no significant changes at the group level.
Alexander Andersson +5 more
wiley +1 more source
ABSTRACT Objective Psychotherapy is the first‐line treatment for eating disorders (EDs), yet only about half of patients benefit long‐term. Bulimia nervosa (BN), Binge‐Eating‐Disorder (BED), and non‐underweight EDs with regular binge eating (> 2 binge‐eating episodes per month within the last 3 months) (OSFED/UFED) form a transdiagnostic group ...
Sebastian M. Max +7 more
wiley +1 more source
Abstract Objective Rare de novo variants in GNAO1 cause a severe neurodevelopmental disorder characterized by a heterogenous display of early onset epilepsy, movement abnormalities, and global developmental delay. More than 100 pathogenic variants in GNAO1 have been identified and categorized into four groups according to their protein features.
Maria Sáez González +12 more
wiley +1 more source
Multimodal acute pain management in the parturient with opioid use disorder: a review.
The opioid epidemic in the United States has led to an increasing number of pregnant patients with opioid use disorder (OUD) presenting to obstetric units.
Ayoub, Mohamad Ibrahim +5 more
core +1 more source
Correlates and Predictors of Binge Eating Disorder in Male Populations: A Systematic Review
ABSTRACT Objective This PRISMA‐compliant systematic review synthesises empirical literature on correlates and predictors of DSM‐5/DSM‐IV Binge Eating Disorder (BED) in male populations (PROSPERO: CRD420250644500). Method Eligible studies used male‐only samples, sex‐stratified analyses, or comparisons involving men with BED.
Sharon L. Grant, Kathleen De Boer
wiley +1 more source
Qualified clinicians previously required a practitioner waiver (i.e., “DATA-waiver” or "X-waiver") to offer buprenorphine, a medication for opioid use disorder (OUD).
Yun Wang +6 more
doaj +1 more source
Assessment and evidence-based treatments for opioid use disorder [PDF]
Clinician Outreach and Communication Activity (COCA) conference call Tuesday, November 29, 2016.One substantial risk associated with prescribing opioids for chronic pain is opioid use disorder (OUD).
core
Bridging the Gap: Treating Opioid Use Disorder in Primary Care
Purpose: This article explores the feasibility of treating Opioid Use Disorder (OUD) in primary care and the benefits and barriers to providing this treatment in this setting. Method: A PubMed literature search was conducted of the following search terms:
Miller, Karla H
core +1 more source
Research progress on the depth of anesthesia monitoring based on the electroencephalogram
Electroencephalogram (EEG) can noninvasive, continuous, and real‐time monitor the state of brain electrical activity, and the monitoring of EEG can reflect changes in the depth of anesthesia (DOA). The development of artificial intelligence can enable anesthesiologists to extract, analyze, and quantify DOA from complex EEG data.
Xiaolan He, Tingting Li, Xiao Wang
wiley +1 more source
BackgroundYouth Opioid Recovery Support (YORS) is a multi-component behavioral treatment approach for youth with opioid use disorder (OUD) with known efficacy on adherence to injectable medications for OUD (MOUD) in young adults. YORS has not been tested
Lexi Taylor +8 more
doaj +1 more source

